Cargando…

Risk factors for osteoporosis in chronic schizophrenia on long-term treatment with antipsychotics: a cross-sectional study

BACKGROUND: Little is known about the laboratory variable risks with bone mineral density (BMD) in patients with schizophrenia. This study was designed to fully investigate the related risk factors for decreased BMD in schizophrenia, as well as evaluate the gender difference of BMD. METHOD: The BMD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Furu, Wu, Ying, Chen, Jindong, Zou, Tianxiang, Qin, Yue, Teng, Ziwei, Su, Yuhan, Wu, Renrong, Huang, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286449/ https://www.ncbi.nlm.nih.gov/pubmed/37344770 http://dx.doi.org/10.1186/s12888-023-04951-1

Ejemplares similares

Osteoporosis Associated with Antipsychotic Treatment in Schizophrenia
por: Wu, Haishan, et al.
Publicado: (2013)

Sex Differences in Psychological Status and Fatigue of Frontline Staff After the COVID-19 Outbreak in China: A Cross-Sectional Study
por: Teng, Ziwei, et al.
Publicado: (2021)

Social support and quality of life among chronically homeless patients with schizophrenia
por: Chen, Jinliang, et al.
Publicado: (2022)

Exploring the associations between behavioral health risk factors, abnormal eating attitudes and socio-demographic factors among Chinese youth: Survey of 7,984 vocational high school students in Hunan in 2020
por: Liu, Jieyu, et al.
Publicado: (2022)

Effects of Clozapine and other Atypical Antipsychotics on Infants Development Who Were Exposed to as Fetus: A Post-Hoc Analysis
por: Shao, Ping, et al.
Publicado: (2015)

Bone Density in Chronic Schizophrenia with Long-Term Antipsychotic Treatment: Preliminary Study
por: Lee, Tae-Young, et al.
Publicado: (2010)

Psychological status and fatigue of frontline staff two months after the COVID-19 pandemic outbreak in China: A cross-sectional study
por: Teng, Ziwei, et al.
Publicado: (2020)

Previous exposure to antipsychotic drug treatment is an effective predictor of metabolic disturbances experienced with current antipsychotic drug treatments
por: Yang, Ye, et al.
Publicado: (2022)

Atypical antipsychotics usage in long-term follow-up of first episode schizophrenia
por: Shrivastava, Amresh, et al.
Publicado: (2012)

Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US
por: O’Day, Ken, et al.
Publicado: (2013)

Long-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials
por: Zhao, Ying Jiao, et al.
Publicado: (2016)

The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
por: Miyamoto, Seiya, et al.
Publicado: (2017)

PM441. Long term atypical antipsychotic treatment improves cognitive performance in schizophrenia but not surpassing conventional antipsychotic drugs effects.
por: Vera, Gabriel Selva, et al.
Publicado: (2016)

Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics
por: Lin, Ching-Hua, et al.
Publicado: (2019)

Family-based case-control study of homotopic connectivity in first-episode, drug-naive schizophrenia at rest
por: Guo, Wenbin, et al.
Publicado: (2017)

Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia
por: Parellada, Eduard, et al.
Publicado: (2012)

Long-acting Injectable Antipsychotics in First-episode Schizophrenia
por: Jeong, Hyun-Ghang, et al.
Publicado: (2013)

Schizophrenia long-acting antipsychotics initiation index (SLAAII)
por: Ifteni, P., et al.
Publicado: (2021)

The place of long-acting injectable antipsychotics in the treatment of schizophrenia
por: Kane, John M., et al.
Publicado: (2023)

Osteopenia and osteoporosis associated with hyperprolactinemic antipsychotics
por: Montejo, A. L., et al.
Publicado: (2023)

Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review
por: Karson, Craig, et al.
Publicado: (2016)

Long-Term Evolution of Metabolic Status in Patients with Schizophrenia Stably Maintained on Second-Generation Antipsychotics
por: Jeong, Seong Hoon, et al.
Publicado: (2018)

Long-term effects of antipsychotics on mortality in patients with schizophrenia: a systematic review and meta-analysis
por: Jia, Ningning, et al.
Publicado: (2022)

Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics and Suicide and All-Cause Mortality in Patients With Newly Diagnosed Schizophrenia
por: Huang, Cheng-Yi, et al.
Publicado: (2021)

Public Behavior Change, Perceptions, Depression, and Anxiety in Relation to the COVID-19 Outbreak
por: Huang, Jing, et al.
Publicado: (2020)

Drugs Based on NMDAR Hypofunction Hypothesis in Schizophrenia
por: Wu, Qiongqiong, et al.
Publicado: (2021)

Reduced Brain Activity in the Right Putamen as an Early Predictor for Treatment Response in Drug-Naive, First-Episode Schizophrenia
por: Wu, Renrong, et al.
Publicado: (2019)

Long Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Bipolar Disorder
por: DEVRİMCİ ÖZGÜVEN, Halise, et al.
Publicado: (2021)

Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
por: Correll, Christoph U., et al.
Publicado: (2021)

Resting-state cerebellar-cerebral networks are differently affected in first-episode, drug-naive schizophrenia patients and unaffected siblings
por: Guo, Wenbin, et al.
Publicado: (2015)

Safety and related factors of treatment with long-term atypical antipsychotic in Chinese patients with schizophrenia: observational study
por: Yu, Wenjuan, et al.
Publicado: (2021)

Inflammatory Response in SARS-CoV-2 Infection of Patients with Schizophrenia and Long-Term Antipsychotic Treatment
por: Moga, Silvia, et al.
Publicado: (2021)

Antipsychotics and risk of natural death in patients with schizophrenia
por: Chen, Yayun, et al.
Publicado: (2019)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

Early non-response as a predictor of later non-response to antipsychotics in schizophrenia: a randomized trial
por: Long, Yujun, et al.
Publicado: (2023)

Hyperactivity of the default-mode network in first-episode, drug-naive schizophrenia at rest revealed by family-based case–control and traditional case–control designs
por: Guo, Wenbin, et al.
Publicado: (2017)

Cognitive effects of atypical antipsychotic drugs in first-episode drug-naïve schizophrenic patients
por: Wang, Juan, et al.
Publicado: (2013)

Antipsychotic patterns in outpatients with schizophrenia in China: A cross sectional study
por: Guo, Xiaobing, et al.
Publicado: (2021)

Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and Cons
por: Kim, Borah, et al.
Publicado: (2012)

Practical Guidance for the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia
por: Riboldi, Ilaria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gq1421ddjj59cqf4k81sb0almm